PDCD1 and gastric cancer: Thus, effective predictive tools and indicators are needed in clinical practice to characterize and select advanced GC patients who are sensitive to PD-1 inhibitor plus chemotherapy, aiming to improve the efficiency of immunotherapy in clinical applications.